Neumora Therapeutics, Inc. (NMRA) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is led by CEO Daljit Singh Aurora, employs 110 people, headquartered in US, publicly traded since 2023.
Neumora Therapeutics, Inc. (NMRA) stock trades at $0.38 with a market capitalization of $71.29M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.41, reflecting a net loss over the last twelve months, price-to-book of 2.08, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.33 and $3.65, and currently trades 89.6% below its 52-week high.
On profitability, Neumora Therapeutics, Inc. generates a return on equity (ROE) of -242.28% (negative, reflecting a net loss), return on capital employed of -216.71%.
Neumora Therapeutics, Inc. by the numbers, 2019–2025
Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-237.0M in 2025.
On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-212.0M.
Borrowings stand at $0, cash from operations was $-206.0M in the latest year, positive in 0 of the last 7.
Return on equity has averaged -52.2% over five years, and was -227.9% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Neumora Therapeutics, Inc. (NMRA) — frequently asked questions
What is Neumora Therapeutics, Inc. (NMRA) stock price today?
Neumora Therapeutics, Inc. (NMRA) is currently trading at $0.38, down 6.48% today.
What is NMRA P/E ratio?
Neumora Therapeutics, Inc.'s P/E ratio is -0.41. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is NMRA return on equity (ROE)?
Neumora Therapeutics, Inc.'s return on equity (ROE) is -242.28%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Neumora Therapeutics, Inc.'s market cap?
Neumora Therapeutics, Inc. has a market capitalization of $71.29M.
Does NMRA pay a dividend?
Neumora Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does NMRA carry?
Neumora Therapeutics, Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is NMRA's profit margin?
Neumora Therapeutics, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is NMRA in?
Neumora Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is NMRA listed on?
Neumora Therapeutics, Inc. trades on NASDAQ under the ticker NMRA.
What is NMRA's 52-week range?
Over the last year Neumora Therapeutics, Inc. has traded between $0.33 and $3.65.
Related Healthcare Stocks
Popular Stocks
Screens NMRA currently matches
On the figures above, Neumora Therapeutics, Inc. passes the filters for 6 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.